TriLink BioTechnologies, a subsidiary of Maravai LifeSciences Holdings Inc., has introduced its first mRNA synthesis kit featuring the innovative CleanCap® capping technology. This new all-in-one IVT kit is designed to deliver up to twice as much mRNA and reduce double-stranded RNA by up to 85% compared to existing kits on the market. The streamlined synthesis process enhances yield and performance. To celebrate the launch, TriLink is donating the initial kits to leading academic institutions in the U.S. and Europe. With over 25 years of experience, TriLink is a leader in nucleic acid product development, playing a vital role in advancing mRNA and oligonucleotide-based therapeutic innovations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。